Figure AI

The conversation explores the topic of humanoid robots and how science fiction is becoming a reality. The principal themes include the advancements in language and visual models, the reduction in mechanical costs, the importance of humanoid shape, the near-term markets for humanoid robots, and the companies involved in this field.Story Notes:Advancements in Language and Visual ModelsThe Importance of Humanoid ShapeNear-Term Markets for Humanoid RobotsFigure AI: Leading the Way in Humanoid RoboticsTo learn more, visit:https://boldcapitalpartners.com/

In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.Story Notes: Addressing the Obesity ChallengeNavigating the Regulatory LandscapeThe Potential Impact on the Pharmaceutical IndustryTo learn more, visit:https://boldcapitalpartners.com/

Insilico Medicine uses generative AI for drug discovery and has set the trend for AI in the pharmaceutical industry. They have developed an AI platform to identify novel targets and molecules, significantly reducing the time and cost of the drug discovery process. The company has a pipeline of novel molecules and drugs, with one asset in clinical trials for idiopathic pulmonary fibrosis (IPF). They’ve gained the trust of the pharma industry and have partnerships with big pharma and contract research organizations.Story Notes:Introduction and Background of Insilico MedicineUnderstanding Generative AIInsilico Medicine's Approach to Drug DiscoveryThe Visionary Leadership of Alex ZhavoronkovTo learn more, visit:https://boldcapitalpartners.com/

In the first episode of Just BOLD Enough, Hosts Teymour Boutros-Ghali and Felicia Hsu discuss their investment thesis and how a disruptive technology can change the face of an industry. They focus on the company Proprio, which has developed a novel real-time surgical navigation device made possible by the convergence of two different industries. They highlight the importance of the team, the market and pain points, and the technological changes that make Proprio's solution possible. The episode concludes with a summary of Proprio's achievements and potential future developments.Story Notes:Investment ThesisTechnology and MarketsIntersection of Social and TechnologySurgical Navigation and ProprioConvergence of TechnologiesData MonetizationTo learn more, visit:https://boldcapitalpartners.com/

In this inaugural episode, Teymour Boutros-Ghali and Felicia Hsu introduce themselves and their new podcast, Just BOLD Enough. They discuss their backgrounds and the history of BOLD Capital, a venture capital firm whose mission is to “disrupt industries while uplifting humanity”. They outline the main themes of the podcast which include: investment philosophy, perspectives on social issues, and thought leadership on relevant topics. The show will feature guests and provide a behind-the-scenes look at the technologies and innovations shaping the future of healthcare and life sciences.Story Notes:Introduction and BackgroundsInvestment Philosophy and ImpactAbout BOLD Capital PartnersOverview of the ShowTo learn more, visit:https://boldcapitalpartners.com/